leflunomide has been researched along with Crohn Disease in 5 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Crohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The primary end point was steroid-free remission, and secondary end points were changes in the Crohn's disease activity index (CDAI) and steroid intake, responsiveness of arthralgias and adverse events." | 2.73 | Treatment of Crohn's disease with leflunomide as second-line immunosuppression : a phase 1 open-label trial on efficacy, tolerability and safety. ( Galle, PR; Gerts, AL; Holtmann, MH; Neurath, MF; Weinman, A, 2008) |
| "Leflunomide was well tolerated and resulted in a significant reduction in the H-B score, global assessment and serologic parameters in 8/12 patients." | 1.32 | Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. ( Binion, DG; Csuka, ME; Emmons, J; Knox, JF; Prajapati, DN; Saeian, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broekaert, IJ | 3 |
| Klein, A | 3 |
| Windschall, D | 3 |
| Rogalski, B | 3 |
| Weller-Heinemann, F | 3 |
| Oommen, P | 3 |
| Küster, M | 3 |
| Foeldvari, I | 3 |
| Minden, K | 3 |
| Hospach, A | 3 |
| Hufnagel, M | 3 |
| Berger, T | 3 |
| Geikowski, T | 3 |
| Quietzsch, J | 3 |
| Horneff, G | 3 |
| Sachar, DB | 1 |
| Prajapati, DN | 1 |
| Knox, JF | 1 |
| Emmons, J | 1 |
| Saeian, K | 1 |
| Csuka, ME | 1 |
| Binion, DG | 1 |
| Thielen, AM | 1 |
| Barde, C | 1 |
| Janer, V | 1 |
| Borradori, L | 1 |
| Saurat, JH | 1 |
| Holtmann, MH | 1 |
| Gerts, AL | 1 |
| Weinman, A | 1 |
| Galle, PR | 1 |
| Neurath, MF | 1 |
1 trial available for leflunomide and Crohn Disease
| Article | Year |
|---|---|
Treatment of Crohn's disease with leflunomide as second-line immunosuppression : a phase 1 open-label trial on efficacy, tolerability and safety.
Topics: Adult; Anti-Inflammatory Agents; Crohn Disease; Drug Therapy, Combination; Female; Follow-Up Studies | 2008 |
4 other studies available for leflunomide and Crohn Disease
| Article | Year |
|---|---|
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Leflunomide in Crohn's disease--the open-label case series and the Texas sharpshooter.
Topics: Crohn Disease; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Treatment Outcome | 2003 |
Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy.
Topics: Adjuvants, Immunologic; Adult; Aged; Crohn Disease; Female; Humans; Immunosuppressive Agents; Isoxaz | 2003 |
Reiter syndrome triggered by adalimumab (Humira) and leflunomide (Arava) in a patient with ankylosing spondylarthropathy and Crohn disease.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Mono | 2007 |